Drugs / ATH-399A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06088784 | Sep 2023 → Apr 2024 | — | HanAll BioPharma Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-25 | HanAll BioPharma Co., Ltd. | Results HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease hanall.com ↗
The study met its primary endpoints of safety and tolerability in 5 different ascending dose groups, demonstrating significant progress in the treatment of this debilitating neurological disorder. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-25 | HanAll BioPharma Co., Ltd. | HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease hanall.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATH-399A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06088784 ↗ |
| Route | Oral | “single oral dose of ATH-399A capsule” NCT06088784 ↗ |